Mivacron (Mivacurium Chloride)

Mivacurium Chloride, the active ingredient in Mivacron, is a non-depolarizing neuromuscular blocker presented as an injectable solution for intravenous use. It provides rapid, short‑acting muscle relaxation to facilitate tracheal intubation and to support surgical procedures or mechanical ventilation in adult patients.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to global quality standards and provides reliable logistics for timely delivery across continents. Clients benefit from comprehensive regulatory support and product traceability throughout the supply chain.

Mivacron is a non‑depolarizing neuromuscular blocker used in the peri‑operative setting to achieve controlled muscle relaxation.

- Facilitation of tracheal intubation: provides rapid onset muscle relaxation allowing safe placement of the endotracheal tube. - Muscle relaxation during surgery: maintains a stable, relaxed surgical field for procedures requiring general anesthesia. - Mechanical ventilation support: sustains adequate muscle paralysis for patients requiring prolonged ventilatory assistance.

Mivacron may be associated with a range of adverse reactions, varying from mild and transient to severe and life‑threatening.

Common Side Effects: - Flushing: transient skin redness often observed shortly after injection. - Histamine release: mild itching or rash due to mediator release. - Transient hypotension: brief decrease in blood pressure that usually resolves without intervention. - Bradycardia: slowing of heart rate that may require monitoring.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate emergency treatment. - Prolonged apnea: extended respiratory muscle paralysis leading to the need for assisted ventilation. - Severe hypotension: marked drop in blood pressure that can compromise organ perfusion.

When using Mivacron, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Assess cholinesterase activity: evaluate patient’s plasma cholinesterase levels before dosing in cases of suspected deficiency. - Monitor neuromuscular function: use quantitative monitoring to gauge depth of blockade and recovery. - Cardiovascular caution: use with care in patients with existing hypotension or bradyarrhythmias. - Hypersensitivity screening: avoid in individuals with known allergy to mivacurium or related compounds. - Adjust for hepatic impairment: consider reduced clearance in severe liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid): - Concurrent neuromuscular blockers: additive muscle paralysis may result in prolonged ventilation. - Aminoglycoside antibiotics: potentiate blockade and increase risk of respiratory failure. - Magnesium sulfate: enhances neuromuscular inhibition and may cause severe hypotension.

Moderate Interactions (Monitor Closely): - Inhalational anesthetics: synergistic effect on muscle relaxation requiring dose adjustment. - Calcium channel blockers: may prolong the duration of action. - Anticholinesterase agents: can antagonize the effect of mivacurium, reducing its efficacy.